216393-63-4 Usage
Uses
Used in Pharmaceutical Industry:
5-Isopropyl-2-Methoxybenzeneboronic Acid is used as a reactant for the synthesis of several biologically active molecules, which have potential applications in the treatment of various diseases.
1. Atherosclerosis Treatment:
5-Isopropyl-2-Methoxybenzeneboronic Acid is used as a reactant for the synthesis of Oxazolidinones, which serve as cholesteryl ester transfer protein inhibitors. These inhibitors are crucial in the treatment of atherosclerosis, a condition characterized by the hardening and narrowing of arteries.
2. Antitumor and Radioprotectants:
The compound is also used in the synthesis of selective quinazolinyl-phenol inhibitors of CHK1. These inhibitors have potential applications as antitumor agents and radioprotectants, offering protection against the harmful effects of radiation and aiding in the treatment of cancer.
3. CETP Inhibitors:
5-Isopropyl-2-Methoxybenzeneboronic Acid is utilized in the production of Biaryl-containing carbamates, which act as CETP (cholesteryl ester transfer protein) inhibitors. These inhibitors play a vital role in managing cholesterol levels and reducing the risk of cardiovascular diseases.
4. MMP Inhibitors:
The compound is also involved in the synthesis of α-Sulfone hydroxamates, which serve as matrix metalloproteinase (MMP) inhibitors. MMP inhibitors have potential applications in the treatment of various conditions, including cancer, arthritis, and neurodegenerative diseases.
Used in Chemical Synthesis:
5-Isopropyl-2-Methoxybenzeneboronic Acid is used as a reactant in Suzuki-Miyaura cross coupling reactions. Specifically, it is involved in the synthesis of 2-nitrobiphenyls using 2-nitroarenediazonium tetrafluoroborate as a coupling partner. This reaction is significant in the field of organic chemistry, as it allows for the formation of new carbon-carbon bonds and the creation of a wide range of chemical compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 216393-63-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,6,3,9 and 3 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 216393-63:
(8*2)+(7*1)+(6*6)+(5*3)+(4*9)+(3*3)+(2*6)+(1*3)=134
134 % 10 = 4
So 216393-63-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H15BO3/c1-7(2)8-4-5-10(14-3)9(6-8)11(12)13/h4-7,12-13H,1-3H3
216393-63-4Relevant academic research and scientific papers
New 5-aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting
Mathieu, Véronique,Van Den Berge, Emilie,Ceusters, Justine,Konopka, Tomasz,Cops, Antonin,Bruyère, Céline,Pirker, Christine,Berger, Walter,Trieu-Van, Tran,Serteyn, Didier,Kiss, Robert,Robiette, Rapha?l
, p. 6626 - 6637 (2013/10/01)
We designed and synthesized 48 aryl-1H-imidazole derivatives and investigated their in vitro growth inhibitory activity in cancer cell lines known to present various levels of resistance to proapoptotic stimuli. The IC50 in vitro growth inhibitory concentration of these compounds ranged from >100 μM to single digit μM. Among the most active compounds, 2i displayed similar in vitro growth inhibition in cancer cells independent of the cells' levels of resistance to proapoptotic stimuli and was found to be cytostatic in melanoma cell lines. Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen, and the NCI COMPARE algorithm did not reveal any correlation between its growth inhibition profiles with the NCI database compound profiles. The use of transcriptomically characterized melanoma models then enabled us to highlight mitochondrial targeting by 2i. This hypothesis was further confirmed by reactive oxygen production measurement and oxygen consumption analysis.
